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Aim: The aim of this study was to synthesize 18FDG in some consecutive runs and check the
quality of manufactured radiopharmaceuticals and to determine the distribution of metallic
impurities in the synthesis process.
Background: For radiopharmaceuticals the general requirements are listed in European Phar-
macopeia and these parameters have to be checked before application for human use.
Materials and methods: Standard methods for the determination of basic characteristics of
radiopharmaceuticals were used. Additionally, high resolution  spectrometry was  used for
the  assessment of nuclidic purity and inductively coupled plasma with mass spectrometry
to  evaluate metallic content.
Results: Results showed sources and distribution of metallic and radiometallic impurities in
the  production process. Main part is trapped in the initial separation column of the synthesis
unit  and is not distributed to the ﬁnal product in signiﬁcant amounts.Conclusions: Produced 18FDG ﬁlled requirements of Ph.Eur. and the content of radionuclidic
and metallic impurities was in the acceptable range.
©  2014 Greater Poland Cancer Centre. Published by Elsevier Urban & Partner Sp. z o.o. All
rights reserved.1.  Background
Positron emission tomography (PET) is a dynamically devel-
oping imaging method of nuclear medicine, which allows to
diagnose metabolic changes in human body. PET diagnostic
techniques use + emitting isotopes for labeling biologically
active compounds and track their distribution in a living
∗ Corresponding author at: Heavy Ion Laboratory, University of Warsaw,
E-mail address: kilian@slcj.uw.edu.pl (K. Kilian).
http://dx.doi.org/10.1016/j.rpor.2014.03.001
1507-1367/© 2014 Greater Poland Cancer Centre. Published by Elsevier organism. Due to its relatively long half-life (110 min), 18F is
the most commonly used radioisotope in PET and is produced
in medical cyclotrons (mostly proton-deuteron 10–20 MeV
machines). Nowadays, the most widely used radiopharmaceu-
tical for diagnostic procedures using PET is 18FDG, the glucose
derivative labeled with 18F, which applications are regularly
reviewed1–7 and standardized.8 Pasteur 5a, 02093 Warsaw, Poland. Tel.: +48 22 55 46 214.
Urban & Partner Sp. z o.o. All rights reserved.
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.  Aim
ne of the most important aspects of working with 18FDG is a
hort time (about 30 min) that can be spent on quality con-
rol and release procedures, thus the speed, simplicity and
eliability of developed analytical methods are critical factors.
or radiopharmaceuticals, the general requirements are listed
n European Pharmacopoeia9 and these parameters have to
e checked before application for human use. Short-lived
adiopharmaceutical preparations may be released before
ompletion of some tests, speciﬁed in individual mono-
raphs. The aim of this study was to synthesize 18F-FDG in
ome consecutive runs and check the quality of manufac-
ured radiopharmaceuticals. Several tests were performed to
etermine chemical and radiochemical impurities, chemical
dentity and other adequate parameters for parenteral formu-
ation. During production process, trace amounts of metallic
adioisotopes are produced due to radio activation on the
etal target housing. In addition, the distribution of metallic
mpurities on synthesis and dispensing module was measured
y gamma spectroscopy and level of non-radioactive metals
as determined with inductively coupled plasma with mass
pectrometry (ICP-MS).
.  Materials  and  methods
.1. 18FDG  manufacturing
8FDG was synthesized in six independent runs with standard
ethod from mannose triﬂate with alkaline hydrolysis as ini-
ially proposed in Ref. 10. Cyclotron GE PETtrace840 with high
ield niobium target (General Electric, Uppsala, Sweden) was
he source of anionic ﬂuorine. Standard produced activity in
8O(p,n)18F reaction with 16.5 MeV  proton beam at 40–45 A,
as 4.0 ± 0.2 Ci (140.6–155.4 GBq) after 120 min  of irradiation
nd was transferred to the GE MXFDG unit (General Electric,
iege, Belgium), where the synthesis and puriﬁcation were
erformed. In the synthesis path, the 18F-ﬂuoride solution
as passed through an ion exchange column, which trapped
nions. Cations, including some metal contaminants, were
ollected with the recovered enriched water. [18F]ﬂuoride was
hen eluted to the reaction vessel with a mixture of potas-
ium carbonate and Kryptoﬁx 2.2.2, then water was removed
y azeotropic distillation with acetonitrile and 18F reacted
ith mannose triﬂate. After alkaline hydrolysis, the solution
as puriﬁed with sequence of C18-RP and alumina columns
nd eluted with water. The ﬁnal product was formulated
ith saline, passed through a 0.22 m ﬁlter and dispensed in
utomatic module DDS-Vials (Tema-Synergie, Italy). Starting
aterials were, ready-to-use, Ph.Eur. compliant kits, obtained
rom ABX (Radeberg, Germany).
.2.  Identiﬁcationdentiﬁcation tests were performed as described in Ref. 9. For
-spectrometry, high resolution germanium detector GMX-
0190-P with digital signal processor (DSPEC, Ortec) and
ammaVison software was used. 2 L sample was appliedtherapy 1 9 ( 2 0 1 4 ) S22–S31 S23
on silica plate, ﬁxed in a holder and inserted into a 5 cm Pb
shielded, low-background housing. Spectra was recorded for
5 min.
Half-life was measured with Atomlab300 (Biodex, USA)
dose calibrator: 300 L (1.2–1.5 GBq) sample was crimped in
penicillin vial, ﬁxed in a standard vial holder and measured in
triplicate at 20 min  intervals.
Identity of manufactured 18FDG was conﬁrmed by compar-
ison of retention time to the certiﬁed reference standard (CRS)
of main compound (ABX, Radeberg, Germany).
3.3.  Radionuclidic  purity
Radionuclidic purity and radionuclidic impurities were deter-
mined using gamma  spectroscopy with a high resolution
germanium detector GMX-20190-P with a digital signal pro-
cessor (DSPEC, Ortec) with GammaVison software. Efﬁciency
and energy calibration was performed with 241Am (255.162 kBq
at the day of measurements), 137Cs (203.425 kBq at the day of
measurements) and 152Eu (260.733 kBq at the day of measure-
ments) sources at 13.9, 17.8, 26.47, 59.67, 121.9, 244.8, 344.37,
661.7, 788.98, 964.13, 1085.92, 1112.17 and 1408.14 keV, respec-
tively. For sources and samples, a universal holder, ﬁxed in
14 cm from a detector window was constructed and located in
a fully shielded (5 cm Pb) low-background housing.
The spectra were recorded in 10,800 s each for ﬁnal prod-
uct and puriﬁcation cartridges used during the synthesis of
2-[18F]FDG: ion exchange columns Accel Plus QMA  Sep-PakTM,
used for preconcentration and separation of 18F from target,
reverse phase separation columns Sep-PakTM C-18 RP used in
a basic hydrolysis and puriﬁcation process of FDG,  alumina
columns Sep-PakTM N Plus for ionic contaminants removal.
Isotopes were identiﬁed on the basis of the characteristic -
emissions. Only for ﬁnal determination of impurities in 18FDG,
the time was extended to 21,600 s. Each peak was analyzed by
marking the region of interest and recording the energy, count
rate and background corrected area.
The -ray spectra for radionuclidic purity test A was
recorded immediately after synthesis and test B was per-
formed 24 h after irradiation. Recorded activities were
calibrated at the end of synthesis (EOS).
The -ray spectra of the residual radionuclides were col-
lected 72 h (36 times the 18F half-life) after irradiation, because
by that time the 18F activity decreased to a level comparable
to longer-lived compounds and did not hamper the spectra
recording.
3.4.  Radiochemical  purity
Radiochemical purity (test A) was performed with an ion
chromatography system ICS-5000+ (Thermo Scientiﬁc, former
Dionex) with a pulsed amperometric detector and radio-
metric detector (GabiStar, Raytest, Germany). 20 L sample
was injected via a manual multiport valve. The separa-
tion was done on Thermo Scientiﬁc Carbopac PA-10 column
(250 mm × 4.0 mm i.d., 10 m),  with 0.1 M NaOH (CO2-free) as
a mobile phase and 1 mL/min ﬂow rate. Data acquisition and
processing was preformed with Chromeleon software.
Radiochemical purity determination (test B) was con-
ducted with a thin layer chromatography system Bioscan
d radiotherapy 1 9 ( 2 0 1 4 ) S22–S31
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.S24  reports of practical oncology an
MiniScan B-MS-100 (Canberra Packard) with Flow-count B-FC-
100 (Canberra Packard) data processing unit. 2 L of sample
were introduced on a silica gel plate and developed on 8 cm
path in a 95:5 acetonitrile–water mixture.
To ensure the quality of measurements, methods were
developed and validated with certiﬁed reference standards
(CRS) of main compound and impurities.
3.4.1.  Isotonicity  and  pH
Isotonicity was determined by cryogenic osmometer (Knauer,
Germany) in 50 L samples. Measurements of pH were con-
ducted with MulitiSeven pH-meter (Mettler-Toledo, Germany)
with microelectrode vs. 4.01, 7.01 and 9.21 buffers (Hamilton,
UK).
3.4.2.  Kryptoﬁx  content
Since the 7th edition the Ph.Eur has replaced in ﬂudeoxyglu-
cose monograph thin-layer chromatographic (TLC) detection
of Kryptoﬁx 2.2.2 with the simple color spot test.11 Silica gel
stripes, immersed in iodoplatinate reagent were used for opti-
cal comparison of color reaction versus pattern (blank, saline,
sample, positive sample) with pass/fail criteria.
3.4.3.  Residual  organic  solvents  content
Head-space gas chromatography was performed on 7890A
Agilent system, equipped with a J&W HP-5 column
(30 m × 0.32 mm × 0.25 m)  and a ﬂame ionization detector
(FID). GC system was supplied with an H2 (30 mL/min) from
CFH200 generator (Peak Scientiﬁc, UK), ensuring 99.9995% of
hydrogen purity, zero-air (400 mL/min) from a Jun-Air 0F301-
4B generator (Jun-Air, UK) and He (6.0, Air Products, ﬂow rate
25 mL/min). Gas chromatographic system was operated at the
following conditions: oven temperature 40 ◦C for 1 min, inlet
temperature 150 ◦C, detector temperature 180 ◦C.
The samples were injected via 7694E Agilent head-space
system. For a comfortable sample application, 5-microliter
single-use capillaries (Drummond Scientiﬁc, USA) were used
for transfer the radioactive sample to 10 mL  penicillin vials
with aluminum caps and PTFE/Si septa (Agilent). Head-space
injector was set to 80 ◦C for 2 min, then sample was equili-
brated for 0.2 min  and transferred to the GC system. The loop
and transfer line were heated to 105 ◦C and 110 ◦C, respectively.
Chemstation software was used for operation of chromato-
graph, acquisition and processing of data.
3.5.  Sterility  and  bacterial  endotoxins
Sterility test was performed by an external microbial lab-
oratory as speciﬁed in Ref. 9. For bacterial endotoxins the
gel-clot method (limit test) was used, where gel formation
indicated the presence of endotoxins. The test was performed
with PyrogentTM set (Lonza, Belgium) The gel formation
in sequence of samples (blank, sample, water spiked with
endotoxins, spiked sample) after 1 h incubation at 37 ◦C was
inspected manually.3.6.  Heavy  metals  determination
Inductively coupled plasma with mass spectrometry (ICP-MS,
Perkin Elmer Elan 9000) was used for the determination of Cu,
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Fig. 1 – Identiﬁcation of 18FDG. (A)  spectra with 18F principal peak; (B) chromatogram of reference solutions. Elution order:
F
F
s
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r
c
tDM (tr = 9.16 min), FDG (tr = 10.38 min), ClDG (tr = 11.19 min).
e, Pb, Ag, Co, Mn,  Cd, Zn, Cr in 18FDG and enriched water
amples. Calibration curves in the range of up to 100 g/L with
our transitive points were prepared. The internal standard,
03Rh was used for minimizing interferences.
.7.  Chemicals
ethanol, ethanol and acetonitrile used for experiment were
C grade and received from Merck. Water used for dilution
as provided from validated MilliQ system and controlled for
he content of organic impurities.
.  Results
.1.  Identiﬁcation
8F was identiﬁed by recording the principal -peak at
10 ± 0.3 keV (Fig. 1a) and determination of half-life
108.8 ± 0.9 min). 18FDG was conﬁrmed, comparing the
etention times of standards, observed in the reference
hromatogram with retention time of the principal signal in
he radiochromatogram (Fig. 1b and c). Recorded retentiontimes were 10.38 min  for the standard and 10.55 min  for the
principal peak.
4.2.  Radionuclidic  purity
Gamma  spectrum recorded for identiﬁcation was used for
determination of radionuclidic purity. Presence of any peaks
with an energy different from 511 keV was checked and,
except signals coming from Pb-X-rays (range 70–80 keV), none
was found. That conﬁrmed a better than 99.9% radionu-
clidic purity. Then 18FDG sample was left for 24 h to decay
the ﬂuorine and again impurities were tested with no sig-
niﬁcant peaks, except traces of 18F. Only about 2 Bq signals
of 51 Cr, 52Mn and 56Co were observed, representing 10−8%
of total 18F activity. Above mentioned results complied
with radionuclidic purity tests A and B.9 Similar levels of
radionuclidic impurities were reported in other papers.12,13,15
When impurities were not found, theoretical content was
calculated by the determination of minimum detectable
activities for all radionuclidic impurities found in the previ-
ous steps of the production. The activity was estimated to
3 kBq.12
More detailed study was conducted on radionuclidic
impurities distribution along the production process with
S26  reports of practical oncology and radiotherapy 1 9 ( 2 0 1 4 ) S22–S31
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Fig. 2 –  spectra with Ge-detector. (a) Recovery 18H2O. QMA  column (A) ﬁrst C18 puriﬁcation column (B), alumina
puriﬁcation column (C), C18 ﬁnal puriﬁcation column (D), ﬁnal product (18FDG) in the energy range: to (b) 500 keV, (c)
500–1000 keV, (d) 1000–1500 keV, and (e) 1500–2500 keV.
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Table 2 – Review of reported radionuclidic impurities in
the recovered 18O water and columns along the 18FDG
synthesis process.
Radionuclide [12] [13] [15] [22] This work
7Be •
48V • •
51Cr • • • •
52Mn • • • • •
54Mn •  • •
55Co •  • •
55Fe •
56Co • • • • •
56Mn •
56Ni •
57Co • • • • •
57Ni •
58Co • • • • •
59Ni •
95Tc • •
95mTc • • • •
96Tc • • • • •
98Tc •
181Re •
182Re • • •
182mRe • •
183Re • • • •
184Re •
186Re •
Total 20 10 9 11 14
Radionuclides speciﬁc for silver targets
105Ag •reports of practical oncology and 
igh resolution -spectrometry. Radionuclidic impurities were
valuated 72 h post-irradiation to remove dominating 18F and
3N by decay. It leaves out as well very short half-life (in the
rder up to tens of minutes) or metastable impurities, gen-
rated from target body and foils during the bombardment,
overing, but not restricted to 50,52mMn, 60,62Cu, 54Co and tech-
etium (92,94mTc).
Samples from the production process: of irradiated water
500 L), ion exchange columns Accel Plus QMA  Sep-PakTM,
everse phase separation columns Sep-PakTM C-18 RP used in
he basic hydrolysis, the same column type used for puriﬁca-
ion process of FDG and alumina columns Sep-PakTM N Plus
ere used to identify radionuclides and their distribution in
8FDG routine production (Fig. 2). List of identiﬁed radionu-
lides, their content in the recovered 18O water and columns
long the synthesis process are collected in Table 1.
The main source of radionuclide impurities in 18FDG pro-
uction is proton beam and secondary neutrons interactions
ith Havar® foil, containing Co (42.5%), Cr (20%), Mn  (1.6%), Mo
2%), Ni (13%), W (2.8%), Fe (18.1%) and traces of carbon. Theo-
etical investigation showed 627 nuclear reactions possible13
ut practical results limited the number of isotopes to prin-
ipal radionuclides and primary proton beam interaction. As
ominating, (p,n) reactions on naturally occurring isotopes are
enerally proposed12,14,16,22 with (p,)12,16,22 and (n,), (n,)22
upplementary paths.
The set of isotopes agreed in literature consists of 52Mn,
4Mn, 56Co, 57Co, 58Co, 96Tc, 183Re and these isotopes are the
ain contributors to activity captured in foil and radiochem-
stry setup. Some isotopes are hardware ﬁngerprints: 109Cd for
ilver targets, 48V in niobium target systems with titanium
oils.15 Distribution of other radionuclides was highly vari-
ble and depended on production parameters (target, proton
nergy and beam current), examined samples (foils, dispos-
ble cassettes, wastes, ﬁnal product) and methodology of
etermination (equipment, time elapsed from end of bom-
ardment (EOB) to measurement).
In this work 15 radioisotopes were identiﬁed in the QMA
olumn. Aside from those mentioned above, 7Be, 51Cr, 55Co,
6Ni, 95mTc, 182Re, 186 Re were found. 96Tc, 56Co and 56Ni were
he main contributors of residual activity with 70% share in
otal column activity (3.120 MBq). Only 6 isotopes were found
n 18O water after passing the QMA: 51Cr, 52Mn, 54Mn, 56Co,
7Co, 58Co with domination of 58Co and signiﬁcant contri-
ution from 52Mn, 56Co and 57Co. Tc and Re isotopes were
ot observed, which could be easily explained by chemical
roperties, where negatively charged perrhenate and pertech-
etate ions are immobilized on QMA  cartridge (Fig. 3). Activity
f 18Owater was 1.400 MBq  (44% of QMA, 30% total activity)
ut individual activities of dominating isotopes were higher
han in the QMA  column, due to the formation of Mn and Co
ationic complexes. Presence of these isotopes in QMA, which
s an anionic exchanger, can be explained by the formation
f hydroxycomplexes in close to neutral pH. A similar pattern
nd distribution (10% of activity in 18O water, ca. 85% trapped
n QMA) were observed in Ref. 12, but reversed proportions
ere found in Ref. 15, conﬁrming high variability in impurities
istribution. In this work 51Cr was mainly trapped in QMA but
as found as well in 18O water, with traces migrating along the
roduction path. This could be related to complex chromium106mAg •
109Cd • • •
equilibria in water and organic solvents and thus the distribu-
tion inconsistency was observed as in other papers.
Interesting was the peak identiﬁed at the energy of
477.606 keV which corresponded to 7Be. The isotope was iden-
tiﬁed only in Ref. 23 without any hypothesis about its origin. In
another paper,22 the 7Be occurrence was explained by proton
bombardment of trace amounts of 12C, present in the Havar
foil. The reaction 12C(p,3n3p)7Be was proposed as a source of
7Be, but requires relatively high, for PET cyclotrons, proton
energies. Anyhow, in this case 7Be should have been observed
by other authors (Table 2).
Reasonable source of 7Be could be natural 10B, found as
chemical impurity in 18O water16 in reaction 10B(p,)7Be.
Boron is a ubiquitous element, common in environment and
widespread in industry. The control of boron levels could not
be efﬁcient due to complex chemistry and numerous applica-
tion in nuclear science and technology. Exact identiﬁcation of
the source is quite difﬁcult, but it would explain why 7Be was
not detected by other authors.
The spectra of the other puriﬁcation columns (carbon and
aluminum) along the production process show <5 Bq peaks
of 51Cr, 52Mn and 56Co. This is a result of signiﬁcant puriﬁca-
tion based on cationic and anionic properties of radiometallic
impurities, where cations are collected in recovery water and
anions are trapped in the QMA column. Residual radionuclidic
impurities are separated and collected in further puriﬁcation
steps, resulting in that only 51Cr, 52Mn and 56Co with activity
in the range of 1–2 Bq could be recorded in the ﬁnal product.
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Decrease of radionuclide impurities along the production
cycle was reported as in other papers,12 as well as the radionu-
clide impurities produced differ depending on the target vessel
materials and even when beam energy is different on the
same target type. These results suggested the necessity of esti-
mating the radionuclides produced for every combination of
proton energy and 18FDG unit using different target vessels.
The most notable is the remarkable reduction of chemi-
cal and radionuclidic impurities when using the Nb-sputtered
Havar foil as compared with the impurities generated when
using a straight Havar foil. Radiometallic impurities were
decreased 10–25 times.16 It did not inﬂuence patients’ safety,
because the majority of contaminants were excluded from the
production process but a 6.4 percent increase in the average
18FDG yield was observed.17
Another isotope, which has to be taken into consideration
is  emitting 3H from 18O(p,3H)16O reaction. But other works
veriﬁed that 3H is not detected in the ﬁnal product and patients
receiving 18FDG do not receive any extra internal exposure
from tritium.15,18
Concluding, all impurities were efﬁciently eliminated from
the ﬁnal product and met  radionuclidic purity set in Ref. 9.
5.  Radiochemical  purity
5.1.  Radiochemical  purity  was  determined  in  all
produced 18FDG  samples
2-chloro-2-deoxy-d-glucose (ClDG, impurity A), 18FDG and
2-18ﬂuoro-2-deoxy-mannose (18FDM) were identiﬁed by ion
chromatography by a qualitative comparison with the refer-
ence solution, containing maximum available concentration
of ClDG, FDG and FDM and determined quantitatively from
6-points calibration curves for each standard. The retention
times were 9.16, 10.38 and 11.19 min, respectively, which corre-
sponded to relative retention factors vs. FDG: 0.88 for FDM andivity in 18H2O and QMA  column.
1.08 for ClDG. Although the regulation for ClDG requests only
pass/fail criteria, the quantitative measurements were done
and average value did not exceed 0.026 mg/V (limit 0.5 mg/V).
18FDG and 18FDM were determined by HPLC with radiometric
detection, where the principal peak of 18FDG was observed at
10.55 min, with 18FDM signal at 9.40 min  and residual 18F at
6.2 min  (Fig. 1c). The average content of 18FDM  was 0.49%.
Six consecutive runs were analyzed in triplicate each.
Free ﬂuoride-18 (Rf = 0.0), 18FDG (Rf = 0.55) and acylated-18FDG
(Rf > 0.85) were determined quantitatively. Typical radiochro-
matogram is presented in Fig. 4. Average content of 18FDG
was 96.80 ± 0.44%, with the lowest result 96.01% and >95%
required in Pharmacopeia. Average content of impurities was
3.2% ± 0.44%.
5.2.  Residual  organic  solvents
Organic solvents were determined with headspace gas chro-
matography (HS-GC). In all samples acetonitrile and ethanol
were determined quantitatively, with traces of methanol
observed in some samples. For the determination, originally
developed method was used, where the separation of organic
solvents was completed in 1 min  (Fig. 5) with total time of
analysis below 4 min, where the pharmacopoeial method or
procedures described in literature require about 20 min  for a
complete separation alone. Detailed results are presented in
Table 3.
The values are comparable to other formulations19,20 which
are not fortiﬁed with ethanol. To check the quality of mea-
surements, three 18F-FDG batches, available on the market,
were analyzed in parallel with manufacturer’s laboratory,
working as commercial 18F-FDG provider, using a standard
Ph.Eur. method, with 20 min  of chromatographic separation.
The results are presented in Table 4 and show good correlation.
However, our proposed method has a better limit of detection
and throughput of samples.
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Fig. 4 – TLC radiochromatogram of 18FDG sample.
Fig. 5 – Chromatogram of residual solvents in 18FDG. Elution order: methanol, ethanol, acetonitrile.
Table 3 – Determined QC parameters in 18F-FDG. Acceptance criteria according to Ref. 9. IU/V: endotoxins unit per
recommended dose in mL;  mg/V: milligrams per recommended dose in mL.
Determined values in n = 6 consecutive runs
Parameter Acceptance criteria Value
Identiﬁcation Principal  peak 511 keV 510.7 ± 0.3 keV
Half-life 105–115 min 108.8 ± 0.9 min
CRS FDG tr = 10.38 min 18FDG tr = 10.55 min
pH 4.5–8.5 6.24–6.75
Radiochemical
purity
18FDG + 18FDM > 95% 98.4 ± 0.8
18FDM < 10% 0.49 ± 0.13
FDG < 0.5 mg/V Pass
ClDG < 0.5 mg/V Pass
TLC 18FDG > 95% 98.6 ± 0.6%
Kryptoﬁx < 2.2 mg/V Pass
Osmolality 280–310 mOsm 293 ± 14 mOsm
Residual solvents Ethanol  < 5000 mg/kg 29 ± 1 mg/kg
Acetonitrile < 4.10 mg/V 0.77 ± 0.03 mg/V
Sterility Sterile Pass
Bacterial endotoxin test <175/V IU/mL Pass
Radionuclidic purity test A 511 keV > 99.9% Pass
Radionuclidic purity test B Impurities < 0.1% Pass
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Table 4 – Comparison of the results with the reference laboratorya for the determination of residual solvents in different
batches of 18F-FDG, manufactured by commercial supplier.
This method Batch 1 Batch 2 Batch 3
LOQ (mg/L) Precision
(%) (n = 6)
Reference
lab (mg/L)
This
method
(mg/L)
Reference
lab (mg/L)
This
method
(mg/L)
Reference
lab  (mg/L)
This
method
(mg/L)
Methanol 3 6.1 N/A <3 N/A <3 N/A <3
Ethanol 3 6.8 <35 23.1 <35 10.6 164 170.1
Acetonitrile 0.4 3.9 <31 5.9 <31 5.6 <31 6.3
LOQ: limit of quantiﬁcation.
a The reference laboratory supplies commercially available 18F-FDG and uses the standard Ph.Eur. method.
Table 5 – Heavy metals content in recovery water and 18FDG samples. EMEA guidelines21 parenteral limit.
LOQ [g/L] Recovery water [g/L] 18FDG [g/L] EMEA guidelines limits [g/L]
Cu 0.09 1.63 ± 0.09 4.6 ± 0.4 5000
Fe 21 <LOQ <LOQ 150
Pb 0.13 14.7 ± 1.3 0.42 ± 0.18 100
Ag 0.18 19.0 ± 0.9 <LOQ N/A
Co 0.11 5.2 ± 0.1 <LOQ 10,000
Mn 0.08 0.52 ± 0.04 0.48 ± 0.10 70,000
Cd 0.15 <LOQ <LOQ 250
Zn 1.1 59 ± 3 250 ± 50 150,000
r
6. Quartuccio N, Treglia G, Salsano M, et al. The role of
ﬂuorine-18-ﬂuorodeoxyglucose positron emissionCr 0.7 3.8 ± 0.4 
LOQ: limit of quantiﬁcation.
5.3.  Heavy  metals  determination
Heavy metal content was determined in six 18FDG samples
and respective recovery water from each run. First, a quanti-
tation limit was determined as an average blank ± 6 standard
deviation. Then determination of 9 heavy metals: Cu, Fe, Pb,
Ag, Co, Mn,  Cd, Zn and Cr in samples was conducted. Summa-
rized values of the quantitation limit are presented in Table 5.
Presented results clearly indicate that the metal impurities
are not a serious threat for the quality of the produced FDG
and are signiﬁcantly lower than set by the regulatory ofﬁce.21
Most of the metallic impurities are concentrated in the ion
exchange column in the inlet or migrate with enriched water
to recovery and do not inﬂuence signiﬁcantly the synthesis
process. A slight increase in the concentration of copper, zinc
and chromium in the ﬁnal product is observed. The ﬁrst two
are common trace contaminants and are difﬁcult to remove
as their probable source is a saline solution used for the ﬁnal
formulation. Increasing concentration of chromium can be
explained by the presence of elements of stainless steel in the
dispensing line.
Isotonicity, pH, Kryptoﬁx content, sterility and endotoxin
test, as generally known procedures are summarized in
Table 3. All parameters were according to the quality criteria
for 18FDG.
6.  Conclusions
All of the impurities were efﬁciently determined and then
18eliminated in the FDG synthesis process, and the ﬁnal
product was puriﬁed from main radionuclidic and metallic
impurities. Final product meets the requirements set by rel-
evant regulations.27.6 ± 1.5 1500
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